<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Increased postprandial <z:mp ids='MP_0001548'>lipemia</z:mp> is part of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> and is associated with <z:hpo ids='HP_0004943'>accelerated atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the effects of the peroxisome proliferator-activated receptor-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> on postprandial <z:mp ids='MP_0001548'>lipemia</z:mp> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A randomized, 8-week, crossover, placebo-controlled, double-blind trial was performed in which <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> at 4 mg was administrated twice daily in 19 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Standardized 6-h oral fat-loading tests were performed after each treatment period </plain></SENT>
<SENT sid="4" pm="."><plain>Postprandial curves were calculated as the total area under the curve (AUC) and the incremental area under the curve (dAUC) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> did not change fasting plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> compared with placebo (1.97 +/- 0.22 vs. 1.88 +/- 0.20 mmol/l, respectively) but decreased postprandial <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels, leading to significantly lower <z:chebi fb="0" ids="17855">triglyceride</z:chebi> dAUC (-37%, P &lt; 0.05), without changing total <z:chebi fb="0" ids="17855">triglyceride</z:chebi> AUC </plain></SENT>
<SENT sid="6" pm="."><plain>Significant postprandial <z:chebi fb="0" ids="17855">triglyceride</z:chebi> reductions in the chylomicron fraction (Svedberg flotation rate [Sf] &gt;400) were achieved with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, which resulted in a significant lower <z:chebi fb="0" ids="17855">triglyceride</z:chebi> AUC (-22%) in this fraction </plain></SENT>
<SENT sid="7" pm="."><plain>The postprandial <z:chebi fb="0" ids="17855">triglyceride</z:chebi> increase in VLDL1 (Sf 60-400) was also lower after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (-27%), but this did not result in a significant lower <z:chebi fb="0" ids="17855">triglyceride</z:chebi> AUC </plain></SENT>
<SENT sid="8" pm="."><plain>In VLDL2 (Sf 20-60), there were no significant differences in <z:chebi fb="0" ids="17855">triglyceride</z:chebi> AUC and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> dAUC between <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and placebo </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> decreased free fatty acid (FFA) AUC (-12%) and FFA dAUC (-18%) compared with placebo </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> improves the metabolism of large <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and decreases postprandial FFA concentrations in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>This may have clinical implications, as these effects may contribute to cardiovascular risk reduction </plain></SENT>
</text></document>